Basic Search
|
Summaries
|
Advanced Search
Violation Tracker Current Parent Company Summary
Current Parent Company Name: Bausch Health
Ownership Structure: publicly traded (ticker symbol BHC)
Headquartered in: Canada
Major Industry: pharmaceuticals
Specific Industry: pharmaceuticals
Penalty total since 2000: $795,555,378
Number of records: 27
| Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
| competition-related offenses | $541,997,876 | 12 |
| financial offenses | $201,005,500 | 5 |
| government-contracting-related offenses | $33,700,000 | 2 |
| healthcare-related offenses | $9,800,000 | 3 |
| employment-related offenses | $7,170,002 | 3 |
| Top 5 Primary Offense Types | Penalty Total | Number of Records |
| price-fixing or anti-competitive practices | $457,750,000 | 8 |
| investor protection violation | $145,000,000 | 1 |
| kickbacks and bribery | $78,647,876 | 3 |
| accounting fraud or deficiencies | $56,000,000 | 3 |
| False Claims Act and related | $33,700,000 | 2 |
Notes: Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the
Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links: For a summary of this company's regulatory penalties in more than 50 other countries, see its Violation Tracker Global summary page
here.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found
here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
| Company | Primary Offense Type | Year | Agency | Penalty Amount  |
| Bausch Health Companies Inc. | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $300,000,000 |
| Valeant Pharmaceuticals International, Inc. | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
| Salix Pharmaceuticals Inc. | kickbacks and bribery | 2016 | USAO | $54,000,000 |
| Bausch Health | accounting fraud or deficiencies | 2020 | SEC | $45,000,000 |
| Valeant Pharmaceuticals International, Inc. | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $37,500,000 |
| Medicis Pharmaceutical Corp. | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $35,000,000 |
| ISTA Pharmaceuticals, Inc. | False Claims Act and related | 2013 | DOJ_CIVIL | $33,500,000 |
| Biovail Pharmaceuticals Inc. | kickbacks and bribery | 2009 | USAO | $24,647,876 |
| Medicis Pharmaceutical Corp. | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $23,000,000 |
| Valeant Pharmaceuticals International, Inc. | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $23,000,000 |
| Bausch & Lomb | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $17,500,000 |
| Valeant Pharmaceuticals International, Inc. | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,750,000 |
| Biovail Corporation | accounting fraud or deficiencies | 2008 | SEC | $10,000,000 |
| Bausch & Lomb Inc. | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $10,000,000 |
| Medicis Pharmaceutical Corporation | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
| Salix Pharmaceuticals Inc. | kickbacks and bribery | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $7,470,000 |
| Medicis Pharmaceutical | employment discrimination | 2016 | private lawsuit-federal | $7,150,000 |
| ICN Pharmaceuticals, Inc. | fraud | 2001 | USAO | $5,600,000 |
| Medicis Pharmaceutical Corporation | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
| Valeant Pharmaceuticals, Inc. | insurance violation | 2018 | CA-INS | $1,875,000 |
| ICN Pharmaceuticals, Inc. | accounting fraud or deficiencies | 2002 | SEC | $1,000,000 |
| ISTA Pharmaceuticals, Inc. | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
| Biovail | False Claims Act and related | 2013 | LA-AG | $200,000 |
| VALEANT PHARMACEUTICALS INTERNATIONAL, INC. | benefit plan administrator violation | 2016 | EBSA | $10,001 |
| BIOVAIL AMERICAS CORP. | benefit plan administrator violation | 2012 | EBSA | $10,001 |
| BAUSCH AND LOMB PHARMACEUTICALS, INC. | workplace safety or health violation | 2000 | OSHA | $7,000 |
| ICN Pharmaceuticals, Inc | economic sanction violation | 2004 | OFAC | $5,500 |
